Stoke Historical Income Statement
| STOK Stock | USD 11.27 0.04 0.35% |
Historical analysis of Stoke Therapeutics income statement accounts such as Interest Expense of 10.4 M, Selling General Administrative of 23.8 M, Total Revenue of 9.2 M or Gross Profit of 4.3 M can show how well Stoke Therapeutics performed in making a profits. Evaluating Stoke Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Stoke Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Stoke Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Stoke Therapeutics is a good buy for the upcoming year.
Stoke |
About Stoke Income Statement Analysis
Stoke Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Stoke Therapeutics shareholders. The income statement also shows Stoke investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Stoke Therapeutics Income Statement Chart
Add Fundamental
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Stoke Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Stoke Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.At this time, Stoke Therapeutics' Cost Of Revenue is quite stable compared to the past year. Reconciled Depreciation is expected to rise to about 2.6 M this year, although the value of Other Operating Expenses will most likely fall to about 68.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 974K | 1.5M | 2.5M | 2.6M | Total Operating Expenses | 86.1M | 116.8M | 123.6M | 68.1M |
Stoke Therapeutics income statement Correlations
Click cells to compare fundamentals
Stoke Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Stoke Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 3.4M | 744K | 120K | 3.1M | 8.8M | 9.2M | |
| Interest Income | 270K | 3.4M | 744K | 120K | 138K | 131.1K | |
| Depreciation And Amortization | 450K | 888K | 974K | 1.5M | 2.5M | 2.6M | |
| Selling General Administrative | 11.9M | 20.8M | 31.9M | 38.9M | 41.3M | 23.8M | |
| Gross Profit | (450K) | (1.9M) | (2.2M) | 12.4M | 4.1M | 4.3M | |
| Other Operating Expenses | 35.7M | 53.0M | 86.1M | 116.8M | 123.6M | 68.1M | |
| Operating Income | (35.7M) | (53.0M) | (86.1M) | (104.4M) | (114.8M) | (109.0M) | |
| Net Income From Continuing Ops | (32.3M) | (52.2M) | (85.8M) | (101.1M) | (103.4M) | (98.2M) | |
| Ebit | (35.7M) | (53.0M) | (86.1M) | (104.4M) | (114.8M) | (109.0M) | |
| Research Development | 23.8M | 32.2M | 54.2M | 77.8M | 82.2M | 44.3M | |
| Ebitda | (35.2M) | (52.2M) | (85.1M) | (102.8M) | (112.3M) | (106.7M) | |
| Cost Of Revenue | 450K | 1.9M | 2.2M | 3.5M | 4.7M | 5.0M | |
| Total Operating Expenses | 35.7M | 53.0M | 86.1M | 116.8M | 123.6M | 68.1M | |
| Reconciled Depreciation | 450K | 888K | 974K | 1.5M | 2.5M | 2.6M | |
| Income Before Tax | (32.3M) | (52.2M) | (85.8M) | (101.1M) | (104.7M) | (99.5M) | |
| Total Other Income Expense Net | 3.4M | 801K | 260K | 3.3M | 10.1M | 10.6M | |
| Net Income Applicable To Common Shares | (32.3M) | (52.2M) | (85.8M) | (101.1M) | (91.0M) | (86.4M) | |
| Net Income | (28.5M) | (50.6M) | (84.7M) | (93.1M) | (104.7M) | (99.5M) | |
| Income Tax Expense | (3.8M) | (1.6M) | (1.1M) | (8.0M) | 4.6M | 4.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.328 | Quarterly Revenue Growth 0.479 | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.